MedPath

Clinical Trial News

HPV Clinical Trial Analysis Reveals Gaps in Prospective Registration and Data Completion

• A cross-sectional analysis of 1632 HPV clinical trials registered between 1999 and 2023 reveals inconsistencies in trial registration practices. • The study highlights a significant number of trials registered retrospectively, failing to adhere to prospective registration guidelines. • Most trials were registered on ClinicalTrials.gov, conducted in North America, and sponsored by hospitals, indicating regional and institutional focus. • The analysis underscores the need for improved adherence to prospective registration and complete data entry to enhance transparency and prevent research misconduct.

FDA Approves Emergent BioSolutions' ACAM2000 for Mpox Prevention in High-Risk Individuals

• The FDA has approved ACAM2000 for the prevention of mpox in individuals at high risk, expanding its original indication for smallpox prevention. • This approval is based on human safety data and a controlled animal study demonstrating ACAM2000's effectiveness against mpox virus exposure. • Emergent BioSolutions is engaging with global health leaders and has offered 50,000 doses of ACAM2000 to Central Africa to combat the mpox outbreak. • ACAM2000, a single-dose vaccine, is administered percutaneously and has been licensed in multiple countries, including the U.S., Canada, and Australia.

DNA Vaccine Shows Promise in Preventing HIV Infection

  • A novel polyvalent DNA/prime-protein boost HIV vaccine (PDPHV) has demonstrated robust immunogenicity in a Phase I clinical trial.
  • The PDPHV vaccine elicited strong and cross-reactive immune responses against multiple HIV subtypes, showing superior results compared to previous HIV vaccines.
  • Researchers isolated a novel human monoclonal antibody (HmAb64) from a vaccinated participant, capable of neutralizing HIV isolates across subtypes.
  • The HmAb64 antibody targets the CD4 binding site on HIV, a challenging but critical target for HIV vaccine development.

Vitamin D Supplementation Significantly Reduces BPPV Recurrence in Older Adults

  • A randomized controlled trial demonstrated an 87% reduction in benign paroxysmal positional vertigo (BPPV) recurrence rates in vitamin D-treated older adults compared to placebo.
  • Participants receiving vitamin D3 supplementation experienced 0.75 fewer clinical BPPV episodes per person-year than those in the placebo group.
  • Time to first BPPV recurrence was significantly longer in the vitamin D treatment group, suggesting improved postural stability and reduced fall risk.
  • The study supports further investigation of vitamin D as a potential standard of care treatment for BPPV patients in future clinical trials.

Qlife's Egoo Health Platform Shows Promise in PKU Monitoring and CRP Testing Amidst Restructuring

  • Qlife Holding AB faces financial restructuring, including bankruptcy filing for its Danish subsidiary, while continuing operations with a focus on its Egoo Health platform.
  • Validation of the C-Reactive Protein (CRP) biomarker on the Egoo Health platform has been finalized with Chinese partner Hipro Biotechnology, initiating clinical testing in China.
  • A research trial at Emory University demonstrated positive data for the Egoo Health platform in monitoring blood data for young women with Phenylketonuria (PKU).
  • Despite financial challenges, Qlife is focusing on supporting Hipro's Egoo Health production and advancing its self-testing immuno-diagnostics platform for the home-hospital segment.

First Patient Dosed in Guard Therapeutics' Phase 2b Study POINTER

Guard Therapeutics has announced the dosing of the first patient in its phase 2b clinical study, POINTER, evaluating RMC-035 as a kidney-protective treatment during open-heart surgery. The study, starting in Canada and expanding to Europe, aims to determine the optimal dosing regimen and target population for RMC-035.

SGLT-2 Inhibitors Linked to Reduced Dementia Risk in Type 2 Diabetes Study

  • A new study suggests that Sodium-glucose cotransporter-2 (SGLT-2) inhibitors, used for treating type 2 diabetes, are associated with a lower risk of developing dementia.
  • The observational study analyzed data from over 200,000 individuals, indicating a potential protective effect of SGLT-2 inhibitors against dementia.
  • Experts emphasize the need for further controlled trials to confirm these findings and to understand the underlying mechanisms of this protective effect.
  • The research adds to the growing evidence linking diabetes management with reduced dementia risk, highlighting the potential for drug repurposing.

Ketamine vs. Fentanyl: Utah Study Aims to Reshape Prehospital Pain Management

  • A clinical trial is underway to compare ketamine and fentanyl for prehospital pain management in trauma patients.
  • The study seeks to determine if ketamine offers advantages over fentanyl, such as fewer side effects and faster recovery.
  • Researchers aim to improve analgesia protocols in emergency settings, potentially enhancing patient comfort and outcomes.
  • Ketamine's potential benefits include a lower risk of respiratory depression and improved blood pressure compared to opioids.

Flexible Parametric Cure Models Enhance Cure Proportion Estimation in Cancer Trials

  • A recent study explores the use of flexible parametric cure models (FPCM) to estimate the proportion of patients cured in cancer clinical trials, offering a more nuanced approach.
  • The research leverages data from the CheckMate 141 trial, which investigated nivolumab in recurrent squamous cell carcinoma of the head and neck, to validate the FPCM methodology.
  • Simulation studies were conducted to assess the performance of FPCM under various scenarios, including finite and asymptotic cure points, to determine optimal model configurations.
  • Findings suggest that FPCM can provide more accurate cure proportion estimates compared to traditional methods like Kaplan-Meier, especially when properly configured with consideration of knot placement.

GATC Health and MCI Partner on AI-Driven Clinical Trial Funding and Insurance Model

  • GATC Health Corp. and Medical and Commercial International (MCI) have partnered to introduce an AI-based financing model for clinical trials, aiming to mitigate financial risks for early-stage drug developers.
  • The model, approved by Lloyd's of London, offers insurance coverage for clinical trial funding in the event of study failure, leveraging GATC's AI to predict drug efficacy and safety.
  • GATC's AI technology simulates human physiology to forecast trial endpoints, enhancing risk assessment accuracy and attracting significant interest from biotech companies and brokerage firms.
  • The collaboration seeks to transform the drug development financial model, facilitating the delivery of safer and more effective treatments for acute medical conditions.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.